Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation

By MarketWatch | Nov 19, 2024 at 07:08 AM EST

Merck & Co.'s stock rose 2% after positive results for a new formulation of cancer drug Keytruda. The trial showed effectiveness of under-the-skin administration. This may help maintain sales for Keytruda, the top-selling drug facing patent expiry in 2028.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.